ESA Biosimilar Effective for Anemia in Hemodialysis Patients
Researchers found “no clinically meaningful differences” in efficacy and safety between the biosimilar epoetin alfa-epbx and epoetin alfa.
Researchers found “no clinically meaningful differences” in efficacy and safety between the biosimilar epoetin alfa-epbx and epoetin alfa.
The risk for premature death increased by 62% and 42% for stage 3 CKD patients with vitamin D deficiency and elevated parathyroid hormone levels, respectively.